[Long-term Efficacy and Safety of Sampeginterferon-ß1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results]. / Dolgosrochnye dannye po effektivnosti i bezopasnosti preparata sampeginterferon-ß1a u patsientov s remittiruyushchim rasseyannym sklerozom: rezul'taty 104-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(2): 52-59, 2023.
Article
de Ru
| MEDLINE
| ID: mdl-36843459
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Sclérose en plaques récurrente-rémittente
/
Interféron bêta-1a
Type d'étude:
Clinical_trials
Limites:
Adolescent
/
Adult
/
Humans
/
Middle aged
Langue:
Ru
Journal:
Zh Nevrol Psikhiatr Im S S Korsakova
Sujet du journal:
NEUROLOGIA
/
PSIQUIATRIA
Année:
2023
Type de document:
Article
Pays d'affiliation:
Russie
Pays de publication:
Russie